Headlines about Mazor Robotics (NASDAQ:MZOR) have been trending somewhat positive this week, Accern reports. The research group scores the sentiment of news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Mazor Robotics earned a coverage optimism score of 0.16 on Accern’s scale. Accern also gave news stories about the medical instruments supplier an impact score of 45.8717336398534 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Here are some of the media headlines that may have impacted Accern’s analysis:
- Financial Analysis: Boston Scientific Corporation (BSX) & Mazor Robotics (NASDAQ:MZOR) (americanbankingnews.com)
- DEADLINE TODAY: Khang & Khang LLP Announces a Securities Class Action Lawsuit against Mazor Robotics Ltd … – GuruFocus.com (gurufocus.com)
- What Kind of Picture Are the Technicals Painting For Mazor Robotics Ltd (MZOR)? – Sheridan Daily (sheridandaily.com)
- DEADLINE TODAY: Khang & Khang LLP Announces a Securities Class Action Lawsuit against Mazor Robotics Ltd. and Reminds Investors with Losses to Contact the Firm (feeds.benzinga.com)
- Stock on Hold Line: Mazor Robotics Ltd. (MZOR) – Street Observer (press release) (streetobserver.com)
Shares of Mazor Robotics (MZOR) opened at 36.87 on Friday. Mazor Robotics has a one year low of $20.19 and a one year high of $45.64. The firm’s 50-day moving average is $38.18 and its 200-day moving average is $32.30. The stock’s market capitalization is $889.05 million.
Mazor Robotics (NASDAQ:MZOR) last announced its quarterly earnings data on Tuesday, August 1st. The medical instruments supplier reported ($0.16) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.25) by $0.09. The business had revenue of $15.46 million during the quarter, compared to the consensus estimate of $15.38 million. Mazor Robotics had a negative return on equity of 28.51% and a negative net margin of 37.66%. The business’s revenue for the quarter was up 86.7% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.09) earnings per share. Equities research analysts forecast that Mazor Robotics will post ($0.77) EPS for the current year.
Several research firms recently issued reports on MZOR. JMP Securities lowered shares of Mazor Robotics from an “outperform” rating to a “market perform” rating in a report on Friday, May 12th. They noted that the move was a valuation call. Needham & Company LLC reissued a “hold” rating on shares of Mazor Robotics in a report on Thursday, July 6th. Ladenburg Thalmann Financial Services reissued a “buy” rating and issued a $46.00 target price on shares of Mazor Robotics in a report on Monday, June 12th. Zacks Investment Research lowered shares of Mazor Robotics from a “hold” rating to a “sell” rating in a report on Tuesday, July 18th. Finally, Standpoint Research lowered shares of Mazor Robotics from a “buy” rating to a “reduce” rating and reduced their target price for the stock from $32.98 to $28.00 in a report on Wednesday, April 19th. They noted that the move was a valuation call. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating and one has issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $33.50.
About Mazor Robotics
Mazor Robotics Ltd is an Israel-based medical device company that develops and markets surgical guidance systems and complementary products. It develops computerized and imaging-based systems in the field of spine surgery. Its products include: Renaissance Surgical Guidance System, which enables surgeons to advance from freehand surgical procedures to guided procedures, as well as Food and Drug Administration (FDA)-cleared and European Conformity (CE)-marked Renaissance System, used in spine surgeries, whether open or minimally invasive, for a number of clinical indications.
Receive News & Ratings for Mazor Robotics Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mazor Robotics Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.